IL240662A0 - Inhibitors of hepatitis C virus co-cycles and cycles - Google Patents

Inhibitors of hepatitis C virus co-cycles and cycles

Info

Publication number
IL240662A0
IL240662A0 IL240662A IL24066215A IL240662A0 IL 240662 A0 IL240662 A0 IL 240662A0 IL 240662 A IL240662 A IL 240662A IL 24066215 A IL24066215 A IL 24066215A IL 240662 A0 IL240662 A0 IL 240662A0
Authority
IL
Israel
Prior art keywords
macrocyclic
hepatitis
virus
bicyclic inhibitors
bicyclic
Prior art date
Application number
IL240662A
Other languages
English (en)
Hebrew (he)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of IL240662A0 publication Critical patent/IL240662A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/02—Preparation by ring-closure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL240662A 2013-03-15 2015-08-18 Inhibitors of hepatitis C virus co-cycles and cycles IL240662A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798961P 2013-03-15 2013-03-15
PCT/US2014/029765 WO2014145095A1 (en) 2013-03-15 2014-03-14 Macrocyclic and bicyclic inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
IL240662A0 true IL240662A0 (en) 2015-10-29

Family

ID=50694007

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240662A IL240662A0 (en) 2013-03-15 2015-08-18 Inhibitors of hepatitis C virus co-cycles and cycles

Country Status (14)

Country Link
US (2) US9617310B2 (https=)
EP (1) EP2970335B1 (https=)
JP (2) JP6511432B2 (https=)
KR (1) KR102215400B1 (https=)
CN (1) CN105073758B (https=)
AU (1) AU2014233390B2 (https=)
BR (1) BR112015021768A2 (https=)
CA (1) CA2902569A1 (https=)
EA (1) EA029088B1 (https=)
ES (1) ES2735355T3 (https=)
IL (1) IL240662A0 (https=)
MX (1) MX2015013224A (https=)
SG (1) SG11201507223TA (https=)
WO (1) WO2014145095A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
CN105503751B (zh) * 2015-12-22 2018-06-05 广西师范大学 一种喹喔啉衍生物的高效合成方法
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
CN111004188B (zh) * 2019-12-18 2021-04-20 安徽红杉生物医药科技有限公司 Ns3/4a蛋白酶抑制剂中间体及其合成方法、应用
CN111018795B (zh) * 2019-12-25 2023-03-28 上海彩迩文生化科技有限公司 一种碱性条件下合成喹喔啉-3-酮的方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
ES2361011T3 (es) 2002-05-20 2011-06-13 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c.
ATE481106T1 (de) 2002-05-20 2010-10-15 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
ES2320771T3 (es) 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CN1788006A (zh) 2003-04-18 2006-06-14 安南塔制药公司 喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂
AU2004240704B9 (en) 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RS51974B (sr) 2004-07-16 2012-02-29 Gilead Sciences Inc. Antivirusna jedinjenja
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
AU2006276246B2 (en) 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
NZ565269A (en) * 2005-08-01 2010-03-26 Merck & Co Inc Macrocyclic peptides as HCV NS3 protease inhibitors
ES2356776T3 (es) 2005-10-11 2011-04-13 Intermune, Inc. Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
AU2007309488B2 (en) 2006-10-24 2012-10-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CA2667146C (en) 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
BRPI0718161A2 (pt) 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20080287449A1 (en) 2007-04-26 2008-11-20 Deqiang Niu Aza-tripeptide hepatitis c serine protease inhibitors
SG174809A1 (en) 2007-05-03 2011-10-28 Intermune Inc Macrocyclic compounds useful as inhibitors of hepatitis c virus
JP2010526834A (ja) 2007-05-10 2010-08-05 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
AP2009005073A0 (en) 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
NZ582096A (en) 2007-06-29 2012-05-25 Gilead Sciences Inc Antiviral compounds that inhibit hepatitis c virus (hcv)
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
WO2009042668A2 (en) 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8106059B2 (en) 2007-10-24 2012-01-31 Virobay, Inc. Substituted pyrazines that inhibit protease cathepsin S and HCV replication
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009070689A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
EP2222161A4 (en) 2007-12-05 2011-09-28 Enanta Pharm Inc QUINOXALINYL DERIVATIVES
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
RU2515318C2 (ru) 2007-12-21 2014-05-10 Авила Терапьютикс, Инк. Ингибиторы протеазы вируса гепатита с и их применение
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
JP2011510927A (ja) 2008-01-24 2011-04-07 エナンタ ファーマシューティカルズ インコーポレイテッド Ｈｃｖセリンプロテアーゼ阻害剤としての二フッ素化トリペプチド
ES2437147T3 (es) 2008-02-04 2014-01-09 Idenix Pharmaceuticals, Inc. Inhibidores de serina proteasa macrocíclicos
CA2714604A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Macrocyclic hcv ns3 protease inhibitors
US8431733B2 (en) 2008-03-12 2013-04-30 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
CN102015652A (zh) 2008-03-20 2011-04-13 益安药业 作为丙型肝炎病毒抑制剂的氟化大环化合物
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
EA019327B1 (ru) * 2008-07-22 2014-02-28 Мерк Шарп Энд Домэ Корп. Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3
KR101647520B1 (ko) 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
CA2734744A1 (en) 2008-08-20 2010-02-25 Michael Eissenstat Hcv protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
PL2331538T3 (pl) 2008-09-16 2014-09-30 Boehringer Ingelheim Int Krystaliczne postacie 2-tiazolylo-4chinolinyl-oksy-pochodnej, silnego inhibitora HCV
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20110075019A (ko) 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
AU2009316472B2 (en) 2008-11-20 2015-07-09 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
CN102223875A (zh) 2008-11-21 2011-10-19 贝林格尔.英格海姆国际有限公司 口服给药的强效hcv抑制剂的药物组合物
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
NZ592705A (en) 2008-12-10 2013-02-22 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20110114582A (ko) 2008-12-19 2011-10-19 길리애드 사이언시즈, 인코포레이티드 Ｈｃｖ ｎｓ３ 프로테아제 억제제
JP5687631B2 (ja) 2008-12-23 2015-03-18 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツドＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｈｃｖのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体
US8936781B2 (en) 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
WO2010135748A1 (en) 2009-05-22 2010-11-25 Sequoia Pharmaceuticals Inc. Bimacrocyclic hcv ns3 protease inhibitors
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
EP2470189A4 (en) 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
CN102741270B (zh) 2009-09-28 2015-07-22 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
US20110082182A1 (en) 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
CN104771364B (zh) 2010-03-10 2018-05-25 艾伯维巴哈马有限公司 固体组合物
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
JP2013528217A (ja) 2010-06-07 2013-07-08 アッヴィ・インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害薬
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US20120094897A1 (en) 2010-09-15 2012-04-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US20130178413A1 (en) 2010-09-21 2013-07-11 John A. McCauley Hcv ns3 protease inhibitors
SG188618A1 (en) 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
US20120095211A1 (en) 2010-09-22 2012-04-19 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
WO2012061248A2 (en) 2010-11-01 2012-05-10 Rfs Pharma, Llc Novel specific hcv ns3 protease inhibitors
JP6034802B2 (ja) 2010-12-14 2016-11-30 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 大環状ラクタムの調製のための方法および中間体
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012166459A1 (en) 2011-05-27 2012-12-06 Bristol-Myers Squibb Company Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2857705A1 (en) 2011-06-16 2012-12-20 AB Pharma Ltd. Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
EP2744331A4 (en) 2011-08-19 2015-01-21 Merck Sharp & Dohme METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN
US20140328799A1 (en) 2011-10-31 2014-11-06 Steven S. Carroll Compositions useful for the treatment of viral diseases
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AU2013208024A1 (en) 2012-01-12 2014-07-10 Boehringer Ingelheim International Gmbh Stabilized pharmaceutical formulations of a potent HCV inhibitor
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с

Also Published As

Publication number Publication date
HK1217196A1 (en) 2016-12-30
ES2735355T3 (es) 2019-12-18
EA029088B1 (ru) 2018-02-28
WO2014145095A1 (en) 2014-09-18
SG11201507223TA (en) 2015-10-29
CN105073758A (zh) 2015-11-18
US20140274884A1 (en) 2014-09-18
CN105073758B (zh) 2017-08-11
BR112015021768A2 (pt) 2016-02-02
EP2970335B1 (en) 2019-05-08
US20170313745A1 (en) 2017-11-02
US9617310B2 (en) 2017-04-11
AU2014233390A1 (en) 2015-09-03
JP2016516069A (ja) 2016-06-02
CA2902569A1 (en) 2014-09-18
JP6511432B2 (ja) 2019-05-15
KR102215400B1 (ko) 2021-02-10
AU2014233390B2 (en) 2018-03-01
EA201591456A1 (ru) 2016-02-29
MX2015013224A (es) 2015-12-11
EP2970335A1 (en) 2016-01-20
JP2019059775A (ja) 2019-04-18
KR20150130456A (ko) 2015-11-23

Similar Documents

Publication Publication Date Title
IL269662A (en) Hepatitis C virus inhibitors
PL3459965T3 (pl) Sposoby przewidywania sekwencji wirusa-przodka i ich zastosowania
SG11201600707QA (en) Substituted aminopyrimidine compounds and methods of use
IL244495B (en) Anti-alpha-synuclein antibodies and methods of use
EP3075001A4 (en) Detectors and methods of using them
IL243478A0 (en) Proximity sensor system and methods for activating them
IL237173B (en) Methods for treating hepatitis b and hepatitis d infections
IL240662A0 (en) Inhibitors of hepatitis C virus co-cycles and cycles
IL244268A0 (en) Heterocyclic compounds and methods of use
PL3019477T3 (pl) Związki heterocykliczne i sposoby ich stosowania
EP2968192A4 (en) Methods and materials for detection of biologicals
IL248318A0 (en) Selective inhibitors that have an effect on the hepatitis virus type c
SG11201507389RA (en) Integration of hydro-dechlorination and hydro-regeneration
GB2521645B (en) Vacuum metallizers and methods of operating vacuum metallizers
TH1401007328A (th) สารยับยั้งมาโครไซคลิกของไวรัส flaviviridae ไวรัส
TH1401007179A (th) องค์ประกอบและการใช้ของมันเพื่อป้องกันและรักษาตับอักเสบบี
GB201321848D0 (en) Lock means and method of use thereof